The biotechnology sector, as measured by the XBI ETF, is trading sharply higher in the pre-market session, driven by positive, high-profile clinical trial results. Merck and Moderna announced significant success in a pivotal personalized cancer therapy trial, causing their stocks to surge and lifting sentiment across the entire biotech industry. This news provides a powerful, sector-specific catalyst, reinforcing a positive narrative for biotech in 2026 which has already been supported by strong M&A activity and other clinical advancements.